Update on prostate pathology

Pathology

Volumn 44, Issue 5, 2012, Pages 391-406

  Osunkoya, Adeboye O ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Biomarkers; Gleason grading system; Needle core biopsies; Primary tumours; Prostate; Radical prostatectomy; Secondary tumours; Treatment effect; Variants

Indexed keywords

TUMOR MARKER;

ADENOCARCINOMA; CANCER GRADING; CANCER STAGING; CONFERENCE PAPER; HUMAN; LABORATORY DIAGNOSIS; MALE; MEDICAL SOCIETY; NEEDLE BIOPSY; PATHOLOGY; PROSTATE; PROSTATE TUMOR; PROSTATECTOMY;

ADENOCARCINOMA; BIOPSY, NEEDLE; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; SOCIETIES, MEDICAL; SPECIMEN HANDLING; TUMOR MARKERS, BIOLOGICAL;

EID: 84866891613     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32835657cf     Document Type: Conference Paper

References (253)

1. Thompson H. Some observations on the anatomy and pathology of the adult prostate, founded upon fifty preparations of the organ, dissected by the author, and accompanying the paper; with two plates. Med Chir Trans 1857; 40: 77-106.
2. Young HH. XV. Cancer of the prostate: A clinical, pathological and postoperative analysis of 111 cases. Ann Surg 1909; 50: 1144-233.
3. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966; 50: 125-8.
4. Bailar JC III, Mellinger GT, Gleason DF. Survival rates of patients with prostatic cancer, tumor stage, and differentiation-preliminary report. Cancer Chemother Rep 1966; 50: 129-36.
5. Mellinger GT, Gleason D, Bailar J 3rd. The histology and prognosis of prostatic cancer. J Urol 1967; 97: 331-7.
6. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111: 58-64.
7. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001; 58: 843-8.
8. Kattan MW, Scardino PT. Prediction of progression: Nomograms of clinical utility. Clin Prostate Cancer 2002; 1: 90-6.
9. Kattan MW, Eastham J. Algorithms for prostate-specific antigen recurrence after treatment of localized prostate cancer. Clin Prostate Cancer 2003; 1: 221-6.
10. McNeal JE. Regional morphology and pathology of the prostate. Am J Clin Pathol 1968; 49: 347-57.
11. McNeal JE. Origin and development of carcinoma in the prostate. Cancer 1969; 23: 24-34.
12. McNeal JE. The prostate and prostatic urethra: A morphologic synthesis. J Urol 1972; 107: 1008-16.
13. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol 1978; 15: 340-5.
14. McNeal JE. The zonal anatomy of the prostate. Prostate 1981; 2: 35-49.
15. Epstein JI, Allsbrook WC Jr, Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-42.
16. Hodge KK, McNeal JE, Terris MK, et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142: 71-4.
17. Bjartell A. Words of wisdom. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Eur Urol 2006; 49: 758-9.
18. Helpap B, Egevad L. The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens. Virchows Arch 2006; 449: 622-7.
19. Billis A, Guimaraes MS, Freitas LL, Meirelles L, Magna LA, Ferreira U. The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies. J Urol 2008; 180: 548-53.
20. Helpap B, Egevad L. Correlation of modified Gleason grading of prostate carcinoma with age, serum prostate specific antigen and tumor extent in needle biopsy specimens. Anal Quant Cytol Histol 2008; 30: 133-8.
21. Uemura H, Hoshino K, Sasaki T, et al. Usefulness of the 2005 International Society of Urologic Pathology Gleason grading system in prostate biopsy and radical prostatectomy specimens. BJU Int 2009; 103: 1190-4.
22. Helpap B, Egevad L. Modified Gleason grading. An updated review. Histol Histopathol 2009; 24: 661-6.
23. Zareba P, Zhang J, Yilmaz A, Trpkov K. The impact of the 2005 International Society of Urological Pathology (ISUP) consensus on Gleason grading in contemporary practice. Histopathology 2009; 55: 384-91.
24. Epstein JI. An update of the Gleason grading system. J Urol 2010; 183: 433-40.
25. Young RH, Clement PB. Sclerosing adenosis of the prostate. Arch Pathol Lab Med 1987; 111: 363-6.
26. Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 1989; 13: 389-96.
27. Jones EC, Clement PB, Young RH. Sclerosing adenosis of the prostate gland. A clinicopathological and immunohistochemical study of 11 cases. Am J Surg Pathol 1991; 15: 1171-80.
28. Gaudin PB, Epstein JI. Adenosis of the prostate. Histologic features in transurethral resection specimens. Am J Surg Pathol 1994; 18: 863-70.
29. Trpkov K, Bartczak-McKay J, Yilmaz A. Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens. Am J Clin Pathol 2009; 132: 211-20.
30. Shah RB. Current perspectives on the Gleason grading of prostate cancer. Arch Pathol Lab Med 2009; 133: 1810-6.
31. Epstein JI. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: A diagnosis that should not be made. Am J Surg Pathol 2000; 24: 477-8.
32. Latour M, Amin MB, Billis A, et al. Grading of invasive cribriform carcinoma on prostate needle biopsy: An interobserver study among experts in genitourinary pathology. Am J Surg Pathol 2008; 32: 1532-9.
33. Lotan TL, Epstein JI. Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy. Hum Pathol 2009; 40: 471-7.
34. Lopez-Beltran A, Mikuz G, Luque RJ, Mazzucchelli R, Montironi R. Current practice of Gleason grading of prostate carcinoma. Virchows Arch 2006; 448: 111-8.
35. Patel AA, Chen MH, Renshaw AA, et al. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA 2007; 298: 1533-8.
36. Epstein JI, Srigley J, Grignon D, et al. Recommendations for the reporting of prostate carcinoma. Hum Pathol 2007; 38: 1305-9.
37. Trpkov K, Zhang J, Chan M, Eigl BJ, Yilmaz A. Prostate cancer with tertiary Gleason pattern 5 in prostate needle biopsy: Clinicopathologic findings and disease progression. Am J Surg Pathol 2009; 33: 233-40.
38. Partin AW, KattanMW, Subong EN, et al. Combination of prostatespecific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 1997; 277: 1445-51.
39. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001; 58: 843-8.
40. Kattan MW, Scardino PT. Prediction of progression: Nomograms of clinical utility. Clin Prostate Cancer 2002; 1: 90-6.
41. Kattan MW, Eastham J. Algorithms for prostate-specific antigen recurrence after treatment of localized prostate cancer. Clin Prostate Cancer 2003; 1: 221-6.
42. Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69: 1095-101.
43. Egevad L, Srigley JR, Delahunt B. International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens: Rationale and organization. Mod Pathol 2011; 24: 1-5.
44. Srigley JR, Humphrey PA, Amin MB, et al. Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med 2009; 133: 1568-76.
45. Kench JG, Clouston DR, Delprado W, et al. Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens. Pathology 2011; 43: 410-9.
46. Epstein JI. The evaluation of radical prostatectomy specimens. Therapeutic and prognostic implications. Pathol Annu 1991; 26: 159-210.
47. Bova GS, Fox WM, Epstein JI. Methods of radical prostatectomy specimen processing: A novel technique for harvesting fresh prostate cancer tissue and review of processing techniques. Mod Pathol 1993; 6: 201-7.
48. Sakr WA, Grignon DJ. Prostate. Practice parameters, pathologic staging and handling radical prostatectomy specimens. Urol Clin North Am 1999; 26: 453-63.
49. Bostwick DG, Montironi R. Evaluating radical prostatectomy specimens: Therapeutic and prognostic importance. Virchows Arch 1997; 430: 1-16.
50. Montironi R, Mazzucchelli R, van der Kwast T. Morphological assessment of radical prostatectomy specimens. A protocol with clinical relevance. Virchows Arch 2003; 442: 211-7.
51. Epstein JI, Amin M, Boccon-Gibod L, et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol 2005; 39: 34-63.
52. Srigley Jr. Key issues in handling and reporting radical prostatectomy specimens. Arch Pathol Lab Med 2006; 130: 303-17.
53. Samaratunga H, Montironi R, True L, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens.Working group 1: Specimen handling. Mod Pathol 2011; 24: 6-15.
54. Myschetzky PS, Suburu RE, Kelly BS Jr et al. Determination of prostate gland volume by transrectal ultrasound: Correlation with radical prostatectomy specimens. Scand J Urol Nephrol 1991; 137: 107-11.
55. Rathaus V, Richter S, Nissenkorn I, Goldberg E. Transperineal ultrasound examination in the evaluation of prostatic size. Clin Radiol 1991; 44: 383-5.
56. Nunez-Nateras R, Andrews JR, Martin GL, et al. Accuracy of ultrasound in estimation of prostate weight: Comparison of urologists and radiologists. Can J Urol 2010; 17: 4985-8.
57. Murphy GP, Busch C, Abrahamsson PA, et al. Histopathology of localized prostate cancer. Consensus conference on diagnosis and prognostic parameters is localized prostate cancer, Stockholm Sweden. Scand J Urol Nephrol 1994; 162: 7-42.
58. Bong GW, Ritenour CW, Osunkoya AO, et al. Evaluation of modern pathological criteria for positive margins in radical prostatectomy specimens and their use for predicting biochemical recurrence. BJU Int 2009; 103: 327-31.
59. Azumi N, Joyce J, Battifora H. Does rapid microwave fixation improve immunohistochemistry? Mod Pathol 1990; 3: 368-72.
60. Leong AS. Microwave fixation and rapid processing in a large throughput histopathology laboratory. Pathology 1991; 23: 271-3.
61. Hafajee ZA, Leong AS. Ultra-rapid microwave-stimulated tissue processing with a modified protocol incorporating microwave fixation. Pathology 2004; 36: 325-9.
62. Chun FK, Briganti A, Lebeau T, et al. The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy. Eur Urol 2006; 49: 273-8.
63. DeCastro GJ, McCann T, Benson MC, et al. Pathologic T2 stage subgroups and recurrence-free survival after radical prostatectomy. Urology 2008; 72: 1214-8.
64. Hong SK, Han BK, Chung JS, et al. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer. BJU Int 2008; 102: 1092-6.
65. Osunkoya AO, Grignon DJ. Practical issues and pitfalls in staging tumors of the genitourinary tract. Semin Diagn Pathol 2012; 29: (in press).
66. van der Kwast TH, Amin MB, Billis A, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol 2011; 24: 16-25.
67. Epstein JI. Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens. J Urol 2011; 186: 790-7.
68. McNeal JE, Bostwick DG, Kindrachuk RA, et al. Patterns of progression in prostate cancer. Lancet 1986; 1: 60-3.
69. Epstein JI, Oesterling JE, Walsh PC. Tumor volume versus percentage of specimen involved by tumor correlated with progression in stage A prostatic carcinoma. J Urol 1988; 139: 980-4.
70. McNeal JE, Price HM, Redwine EA, et al. Stage A versus stage B adenocarcinoma of the prostate: Morphological comparison and biological significance. J Urol 1988; 139: 61-5.
71. Partin AW, Epstein JI, Cho KR, et al. Morphometric measurement of tumor volume and percent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer. J Urol 1989; 141: 341-5.
72. Humphrey PA, Vollmer RT. Intraglandular tumor extent and prognosis in prostatic carcinoma: Application of a grid method to prostatectomy specimens. Hum Pathol 1990; 21: 799-804.
73. Vollmer RT. Percentage of tumor in prostatectomy specimens: A study of American Veterans. Am J Clin Pathol 2009; 131: 86-91.
74. Billis A. Fat invasion in ten-core prostate needle biopsies: Incidence, biopsy and clinical findings. Int Braz J Urol 2004; 30: 346-7.
75. Sung MT, Eble JN, Cheng L. Invasion of fat justifies assignment of stage pT3a in prostatic adenocarcinoma. Pathology 2006; 38: 309-11.
76. Miller JS, Chen Y, Ye H, et al. Extraprostatic extension of prostatic adenocarcinoma on needle core biopsy: Report of 72 cases with clinical follow-up. BJU Int 2010; 106: 330-3.
77. Magi-Galluzzi C, Evans AJ, Delahunt B, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: Extraprostatic extension, lymphovascular invasion and locally advanced disease. Mod Pathol 2011; 24: 26-38.
78. Cohen RG, Stables S. Intraprostatic fat. Hum Pathol 1998; 29: 424-5.
79. Nazeer T, Kee KH, Ro JY, et al. Intraprostatic adipose tissue: A study of 427 whole mount radical prostatectomy specimens. Hum Pathol 2009; 40: 538-41.
80. Evans AJ, Henry PC, Van der Kwast TH, et al. Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol 2008; 32: 1503-12.
81. Ye H, Walsh PC, Epstein JI. Skeletal muscle involvement by limited Gleason score 6 adenocarcinoma of the prostate on needle biopsy is not associated with adverse findings at radical prostatectomy. J Urol 2010; 184: 2308-12.
82. Epstein JI, Carmichael MJ, Pizov G, et al. Influence of capsular penetration on progression following radical prostatectomy: A study of 196 cases with long-term follow-up. J Urol 1993; 150: 135-41.
83. Wheeler TM, Dillioglugil O, Kattan MW, et al. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol 1998; 29: 856-62.
84. Davis BJ, Pisansky TM, Wilson TM, et al. The radial distance of extraprostatic extension of prostate carcinoma: Implications for prostate brachytherapy. Cancer 1999; 85: 2630-7.
85. Sohayda C, Kupelian PA, Levin HS, et al. Extent of extracapsular extension in localized prostate cancer. Urology 2000; 55: 382-6.
86. Sung MT, Lin H, Koch MO, et al. Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer. Am J Surg Pathol 2007; 31: 311-8.
87. Greene FL. The American Joint Committee on Cancer: Updating the strategies in cancer staging. Bull Am Coll Surg 2002; 87: 13-5.
88. Rodriguez-Covarrubias F, Larre S, Dahan M, et al. Invasion of bladder neck after radical prostatectomy: One definition for different outcomes. Prostate Cancer Prostatic Dis 2008; 11: 294-7.
89. Buschemeyer WC 3rd, Hamilton RJ, Aronson WJ, et al. Is a positive bladder neck margin truly a T4 lesion in the prostate specific antigen era? Results from the SEARCH Database. J Urol 2008; 179: 124-9.
90. Zhou M, Reuther AM, Levin HS, et al. Microscopic bladder neck involvement by prostate carcinoma in radical prostatectomy specimens is not a significant independent prognostic factor. Mod Pathol 2009; 22: 385-92.
91. Ruano T, Meirelles L, Freitas LL, et al. The significance of microscopic bladder neck invasion in radical prostatectomies: PT4 disease? Int Urol Nephrol 2009; 41: 71-6.
92. Edge SB, Byrd DR, Carducci M, et al., editors. AJCC Cancer Staging Manual. 7th ed. Springer: New York, 2010.
93. Cheng L, Jones TD, Lin H, et al. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. J Urol 2005; 174: 2181-5.
94. McNeal JE, Yemoto CE. Significance of demonstrable vascular space invasion for the progression of prostatic adenocarcinoma. Am J Surg Pathol 1996; 20: 1351-60.
95. Shariat SF, Khoddami SM, Saboorian H, et al. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. J Urol 2004; 171: 1122-7.
96. Bates AW, Baithun SI. Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: Clinicopathological and histological features of 282 cases. Histopathology 2000; 36: 32-40.
97. Bowrey DJ, Otter MI, Billings PJ. Rectal infiltration by prostatic adenocarcinoma: Report on six patients and review of the literature. Ann R Coll Surg Engl 2003; 85: 382-5.
98. Lane Z, Epstein JI, Ayub S, et al. Prostatic adenocarcinoma in colorectal biopsy: Clinical and pathologic features. Hum Pathol 2008; 39: 543-9.
99. Hoffman JR, Firoozmand E, Luthringer DJ, et al. Carcinoma of the prostate with aggressive rectal invasion. Am Surg 2009; 75: 434-6.
100. Debras B, Guillonneau B, Bougaran J, et al. Prognostic significance of seminal vesicle invasion on the radical prostatectomy specimen. Rationale for seminal vesicle biopsies. Eur Urol 1998; 33: 271-7.
101. Tefilli MV, Gheiler EL, Tiguert R, et al. Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer. J Urol 1998; 160: 802-6.
102. Potter SR, Epstein JI, Partin AW. Seminal vesicle invasion by prostate cancer: Prognostic significance and therapeutic implications. Rev Urol 2000; 2: 190-5.
103. Berney DM, Wheeler TM, Grignon DJ, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: Seminal vesicles and lymph nodes. Mod Pathol 2011; 24: 39-47.
104. Datta K, Muders M, Zhang H, Tindall DJ. Mechanism of lymph node metastasis in prostate cancer. Future Oncol 2010; 6: 823-36.
105. Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185: 869-75.
106. Cheng L, Bergstralh EJ, Cheville JC, et al. Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol 1998; 22: 1491-500.
107. Boormans JL, Wildhagen MF, Bangma CH, et al. Histopathological characteristics of lymph node metastases predict cancer-specific survival in nodepositive prostate cancer. BJU Int 2008; 102: 1589-93.
108. Chuang AY, Epstein JI. Positive surgical margins in areas of capsular incision in otherwise organ confined disease at radical prostatectomy: Histologic features and pitfalls. Am J Surg Pathol 2008; 32: 1201-6.
109. Tan PH, Cheng L, Srigley JR, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: Surgical margins. Mod Pathol 2011; 24: 48-57.
110. Epstein JI. Evaluation of radical prostatectomy capsular margins of resection. The significance of margins designated as negative, closely approaching, and positive. Am J Surg Pathol 1990; 14: 626-32.
111. Emerson RE, Koch MO, Daggy JK, et al. Closest distance between tumor and resection margin in radical prostatectomy specimens: Lack of prognostic significance. Am J Surg Pathol 2005; 29: 225-9.
112. Grignon DJ. Unusual subtypes of prostate cancer. Mod Pathol 2004; 17: 316-27.
113. Mazzucchelli R, Lopez-Beltran A, Cheng L, et al. Rare and unusual histological variants of prostatic carcinoma: Clinical significance. BJU Int 2008; 102: 1369-74.
114. Epstein JI, Lieberman PH. Mucinous adenocarcinoma of the prostate gland. Am J Surg Pathol 1985; 9: 299-308.
115. Ro JY, Grignon DJ, Ayala AG, et al. Mucinous adenocarcinoma of the prostate: Histochemical and immunohistochemical studies. Hum Pathol 1990; 21: 593-600.
116. Osunkoya AO, Epstein JI. Primary mucin-producing urothelial-type adenocarcinoma of prostate: Report of 15 cases. Am J Surg Pathol 2007; 31: 1323-9.
117. Osunkoya AO, Nielsen ME, Epstein JI. Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: A study of 47 cases. Am J Surg Pathol 2008; 32: 468-72.
118. Lane BR, Magi-Galluzzi C, Reuther AM, et al. Mucinous adenocarcinoma of the prostate does not confer poor prognosis. Urology 2006; 68: 825-30.
119. Osunkoya AO, Adsay NV, Cohen C, Epstein JI, Smith SL. MUC2 expression in primary mucinous and nonmucinous adenocarcinoma of the prostate: An analysis of 50 cases on radical prostatectomy. Mod Pathol 2008; 21: 789-94.
120. Melicow MM, Pachter MR. Endometrial carcinoma of prostatic utricle (uterus masculinus). Cancer 1967; 20: 1715-22.
121. Bostwick DG, Kindrachuk RW, Rouse RV. Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings. Am J Surg Pathol 1985; 9: 595-609.
122. Epstein JI, Woodruff JM. Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohistochemical study of ten cases. Cancer 1986; 57: 111-9.
123. Ro JY, Ayala AG, Wishnow KI, Ordonez NG. Prostatic duct adenocarcinoma with endometrioid features: Immunohistochemical and electron microscopic study. Semin Diagn Pathol 1988; 5: 301-11.
124. Amin A, Epstein JI. Pathologic stage of prostatic ductal adenocarcinoma at radical prostatectomy: Effect of percentage of the ductal component and associated grade of acinar adenocarcinoma. Am J Surg Pathol 2011; 35: 615-9.
125. Tavora F, Epstein JI. High-grade prostatic intraepithelial neoplasia like ductal adenocarcinoma of the prostate: A clinicopathologic study of 28 cases. Am J Surg Pathol 2008; 32: 1060-7.
126. Lee TK, Miller JS, Epstein JI. Rare histological patterns of prostatic ductal adenocarcinoma. Pathology 2010; 42: 319-24.
127. Kovi J, Jackson MA, Heshmat MY. Ductal spread in prostatic carcinoma. Cancer 1985; 56: 1566-73.
128. McNeal JE, Yemoto CE. Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. Am J Surg Pathol 1996; 20: 802-14.
129. Guo CC, Epstein JI. Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance. Mod Pathol 2006; 19: 1528-35.
130. Cohen RJ, Wheeler TM, Bonkhoff H, Rubin MA. A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma. Arch Pathol Lab Med 2007; 131: 1103-9.
131. Henry PC, Evans AJ. Intraductal carcinoma of the prostate: A distinct histopathological entity with important prognostic implications. J Clin Pathol 2009; 62: 579-83.
132. Scott WW, Benjamin JA. A comparative follow-up study of the therapeutic value of bilateral orchiectomy in the treatment of carcinoma of the prostate gland. J Urol 1948; 60: 604-11.
133. O'Connor VJ, Sokol JK. Bilateral orchiectomy in the treatment of carcinoma of the prostate. Am J Surg 1960; 99: 573-9.
134. Klugo RC, Farah RN, Cerny JC. Bilateral orchiectomy for carcinoma of prostate. Response of serum testosterone and clinical response to subsequent estrogen therapy. Urology 1981; 17: 49-50.
135. Pollen JJ. Endocrine treatment of prostatic cancer. Urology 1983; 21: 555-8.
136. Crawford ED. Hormonal therapy of prostatic carcinoma. Defining the challenge. Cancer 1990; 66 (5 Suppl): 1035-8.
137. Faure N, Lemay A, Laroche B, et al. Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma. Prostate 1983; 4: 601-24.
138. Crawford ED. Combined androgen blockade. Urology 1989; 34 (4 Suppl): 46-56.
139. Auclerc G, Antoine EC, Cajfinger F, et al. Management of advanced prostate cancer. Oncologist 2000; 5: 36-44.
140. Fluchter SH, Weiser R, Gamper C. The role of hormonal treatment in prostate cancer. Recent Results Cancer Res 2007; 175: 211-37.
141. Petraki CD, Sfikas CP. Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. Histol Histopathol 2007; 1: 107-18.
142. Epstein JI, Netto GJ. Biopsy Interpretation of the Prostate. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins, 2008.
143. Tetu B. Morphological changes induced by androgen blockade in normal prostate and prostatic carcinoma. Best Prac Res Clin Endo Metab 2008; 22: 271-83.
144. Evans AJ, Ryan P, Van derKwast T. Treatment effects in the prostate including those associated with traditional and emerging therapies. Adv Anat Pathol 2011; 18: 281-93.
145. Parwani AV, Kronz JD, Genega EM, et al. Prostate carcinoma with squamous differentiation: An analysis of 33 cases. Am J Surg Pathol 2004; 28: 651-7.
146. Ito T, Yamamoto S, Ohno Y, et al. Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence. Oncol Rep 2001; 8: 1221-4.
147. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004; 45: 586-92.
148. Alberti C. Neuroendocrine differentiation in prostate carcinoma: Focusing on its pathophysiologic mechanisms and pathological features. G Chir 2010; 31: 568-74.
149. Berruti A, Bollito E, Cracco CM, et al. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy. Prostate 2010; 70: 718-26.
150. Bagshaw MA, Kaplan ID, Cox RC. Prostate cancer. Radiation therapy for localized disease. Cancer 1993; 71 (3 Suppl): 939-52.
151. Zagars GK, von Eschenbach AC, Ayala AG. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer 1993; 72: 1709-25.
152. Pollack A, Smith LG, von Eschenbach AC. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 2000; 48: 507-12.
153. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 25-33.
154. Nilsson S, Norlén BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 2004; 43: 316-81.
155. Pisansky TM. External-beam radiotherapy for localized prostate cancer. N Engl J Med 2006; 355: 1583-91.
156. Crook J. Radiotherapy for prostate cancer: How do we define success? Can J Urol 1997; 4 (2 Supp 1): 48-53.
157. Crook J, Malone S, Perry G, et al. Postradiotherapy prostate biopsies: What do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000; 48: 355-67.
158. Patel H, Peddada AV, Zimmern PE, Hernandez R, Kagan R. Risk of incontinence with transurethral resection of the prostate after radiation therapy for prostate cancer. J Surg Oncol 1997; 64: 127-9.
159. Kollmeier MA, Stock RG, Cesaretti J, Stone NN. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. J Urol 2005; 173: 808-12.
160. Cheng L, Cheville JC, Pisansky TM, et al. Prevalence and distribution of prostatic intraepithelial neoplasia in salvage radical prostatectomy specimens after radiation therapy. Am J Surg Pathol 1999; 23: 803-8.
161. Leonardo C, Simone G, Papalia R, et al. Salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. Int J Urol 2009; 16: 584-6.
162. Seabra D, Faria E, Dauster B, Rodrigues G, Fava G. Critical analysis of salvage radical prostatectomy in the management of radioresistant prostate cancer. Int Braz J Urol 2009; 35: 43-8.
163. Heidenreich A, Richter S, Thuer D, Pfister D. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol 2010; 57: 437-43.
164. Bostwick DG, Egbert BM, Fajardo LF. Radiation injury of the normal and neoplastic prostate. Am J Surg Pathol 1982; 6: 541-51.
165. Gaudin PB, Zelefsky MJ, Leibel SA, Fuks Z, Reuter VE. Histopathologic effects of three-dimensional conformal external beamradiation therapy on benign and malignant prostate tissues. Am J Surg Pathol 1999; 23: 1021-31.
166. Magi-Galluzzi C, Sanderson H, Epstein JI. Atypia in non neoplastic prostate glands after radiotherapy for prostate cancer: Duration of atypia and relation to type of radiotherapy. Am J Surg Pathol 2003; 27: 206-12.
167. Bostwick DG, Cheng L, editors. Urologic Surgical Pathology. 2nd ed. New York: Elsevier/Mosby, 2008.
168. Shinohara K. Cryotherapy. Int J Clin Oncol 2007; 12: 416-26.
169. Ritch CR, Katz AE. Update on cryotherapy for localized prostate cancer. Curr Urol Rep 2009; 10: 206-11.
170. Pisters LL. Cryotherapy for prostate cancer: Ready for prime time? Curr Opin Urol 2010; 20: 218-22.
171. Truesdale MD, Cheetham PJ, Hruby GW, et al. An evaluation of patient selection criteria on predicting progression-free survival after primary focal unilateral nerve-sparing cryoablation for prostate cancer: Recommendations for follow up. Cancer J 2010; 16: 544-9.
172. Tsivian M, Polascik TJ. Focal cryotherapy for prostate cancer. Curr Urol Rep 2010; 11: 147-51.
173. Jones JS. Focal or subtotal therapy for early stage prostate cancer. Curr Treat Options Oncol 2007; 8: 165-72.
174. Yoon GS, Wang W, Osunkoya AO, et al. Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. J Urol 2008; 179: 2203-6.
175. Borkowski P, Robinson MJ, Poppiti RJ Jr, Nash SC. Histologic findings in postcryosurgical prostatic biopsies. Mod Pathol 1996; 9: 807-11.
176. Chin JL, Touma N, Pautler SE, et al. Serial histopathology results of salvage cryoablation for prostate cancer after radiation failure. J Urol 2003; 170: 1199-202.
177. Izawa JI, Busby JE, Morganstern N, et al. Histological changes in prostate biopsies after salvage cryotherapy: Effect of chronology and the method of biopsy. BJU Int 2006; 98: 554-8.
178. Tetu B, Ro JY, Ayala AB, et al. Small cell carcinoma of the prostate. Part 1. A clinicopathologic study of 20 cases. Cancer 1987; 59: 1803-9.
179. Christopher ME, Seftel AD, Sorenson K, Resnick MI. Small cell carcinoma of the genitourinary tract: An immunohistochemical, electron microscopic and clinicopathological study. J Urol 1991; 146: 382-8.
180. Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: A clinical, pathological and immunohistological study of 27 patients. J Urol 1992; 147: 804-7.
181. Nadig SN, Deibler AR, El Salamony TM, et al. Small cell carcinoma of the prostate: An underrecognized entity. Can J Urol 2001; 8: 1207-10.
182. WangW, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008; 32: 65-71.
183. Wenk RE, Bhagavan BS, Levy R, et al. Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia. Cancer 1977; 40: 773-8.
184. Valle J, von Boguslawsky K, Stenborg M, Andersson LC. Progression from adenocarcinoma to small cell carcinoma of the prostate with normalization of prostate-specific antigen (PSA) levels. Scand J Urol Nephrol 1996; 30: 509-12.
185. Miyoshi Y, Uemura H, Kitami K, et al. Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy. BJU Int 2001; 88: 982-3.
186. Nemoto K, Tomita Y. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy. Scand J Urol Nephrol 2007; 41: 558-60.
187. Han B, Mehra R, Suleman K, et al. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol 2009; 22: 1176-85.
188. Scheble VJ, Braun M, Wilbertz T, et al. ERG rearrangement in small cell prostatic and lung cancer. Histopathology 2010; 56: 937-43.
189. Guo CC, Dancer JY, Wang Y, et al. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol 2011; 42: 11-7.
190. Lotan TL, Gupta NS, Wang W, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011; 24: 820-8.
191. Williamson SR, Zhang S, Yao JL, et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: Evidence supporting monoclonal origin. Mod Pathol 2011; 24: 1120-7.
192. Grignon DJ, Ro JY, Ordonez NG, et al. Basal cell hyperplasia, adenoid basal cell tumor, and adenoid cystic carcinoma of the prostate gland: An immunohistochemical study. Hum Pathol 1988; 19: 1425-33.
193. Iczkowski KA, Ferguson KL, Grier DD, et al. Adenoid cystic/basal cell carcinoma of the prostate: Clinicopathologic findings in 19 cases. Am J Surg Pathol 2003; 27: 1523-9.
194. McKenney JK, Amin MB, Srigley JR, et al. Basal cell proliferations of the prostate other than usual basal cell hyperplasia: A clinicopathologic study of 23 cases, including four carcinomas, with a proposed classification. Am J Surg Pathol 2004; 28: 1289-98.
195. Hosler GA, Epstein JI. Basal cell hyperplasia: An unusual diagnostic dilemma on prostate needle biopsies. Hum Pathol 2005; 36: 480-5.
196. Ali TZ, Epstein JI. Basal cell carcinoma of the prostate: A clinicopathologic study of 29 cases. Am J Surg Pathol 2007; 31: 697-705.
197. Yang XJ, McEntee M, Epstein JI. Distinction of basaloid carcinoma of the prostate from benign basal cell lesions by using Immunohistochemistry for bcl-2 and Ki-67. Hum Pathol 1998; 29: 1447-50.
198. Greene LF, O'Dea MJ, Dockerty MB. Primary transitional cell carcinoma of the prostate. J Urol 1976; 116: 761-3.
199. Algaba F, Santanlaria JM, Lamas M, Ayala G. Transitional cell carcinoma of the prostate. Eur Urol 1985; 11: 87-90.
200. Cheville JC, Dundore PA, Bostwick DG, et al. Transitional cell carcinoma of the prostate: Clinicopathologic study of 50 cases. Cancer 1998; 82: 703-7.
201. Tran KP, Epstein JI. Mucinous adenocarcinoma of urinary bladder type arising from the prostatic urethra. Distinction from mucinous adenocarcinoma of the prostate. Am J Surg Pathol 1996; 20: 1346-50.
202. Ortiz-Rey JA, Dos Santos JE, Rodríguez-Castilla M, Alvarez C, Farina L. Mucinous urothelial-type adenocarcinoma of the prostate. Scand J Urol Nephrol 2004; 38: 256-7.
203. Curtis MW, Evans AJ, Srigley Jr. Mucin-producing urothelial-type adenocarcinoma of prostate: Report of two cases of a rare and diagnostically challenging entity. Mod Pathol 2005; 18: 585-90.
204. Osunkoya AO, Netto GJ, Epstein JI. Colorectal adenocarcinoma involving the prostate: Report of 9 cases. Hum Pathol 2007; 38: 1836-41.
205. Eble JN, Sauter G, Epstein JI, et al., editors. The World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004.
206. Herawi M, Epstein JI. Specialized stromal tumors of the prostate: A clinicopathologic study of 50 cases. Am J Surg Pathol 2006; 30: 694-704.
207. Hansel DE, Herawi M, Montgomery E, Epstein JI. Spindle cell lesions of the adult prostate. Mod Pathol 2007; 20: 148-58.
208. Nagar M, Epstein JI. Epithelial proliferations in prostatic stromal tumors of uncertain malignant potential (STUMP). Am J Surg Pathol 2011; 35: 898-903.
209. Johnson DE, Chalbaud R, Ayala AG. Secondary tumors of the prostate. J Urol 1974; 112: 507-8.
210. Zein TA, Huben R, Lane W, Pontes JE, Englander LS. Secondary tumors of the prostate. J Urol 1985; 133: 615-6.
211. Bates AW, Baithun SI. Secondary solid neoplasms of the prostate: A clinico-pathological series of 51 cases. Virchows Arch 2002; 440: 392-6.
212. Schellhammer PF, Bean MA, Whitmore WF Jr. Prostatic involvement by transitional cell carcinoma: Pathogenesis, patterns and prognosis. J Urol 1977; 118: 399-403.
213. Revelo MP, Cookson MS, Chang SS, et al. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: Implications for possible apical sparing surgery. J Urol 2004; 171: 646-51.
214. Oliva IV, Smith SL, Chen Z, Osunkoya AO. Urothelial carcinoma of the bladder with transmural and direct prostatic stromal invasion: Does extent of stromal invasion significantly impact patient outcome? Hum Pathol 2011; 42: 51-6.
215. Chuang AY, DeMarzo AM, Veltri RW, et al. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol 2007; 31: 1246-55.
216. Madden JF, Burchette JL, Raj GV, et al. Anterior rectal wall gastrointestinal stromal tumor presenting clinically as prostatic mass. Urol Oncol 2005; 23: 268-72.
217. Long Q, Johnson BA, Osunkoya AO, et al. Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy. Am J Pathol 2011; 179: 46-54.
218. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005; 23: 7005-12.
219. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006; 98: 715-7.
220. Stein BS, Vangore S, Petersen RO, Kendall AR. Immunoperoxidase localization of prostate-specific antigen. Am J Surg Pathol 1982; 6: 553-7.
221. Bates RJ, Chapman CM, Prout GR Jr, Lin CW. Immunohistochemical identification of prostatic acid phosphatase: Correlation of tumor grade with acid phosphatase distribution. J Urol 1982; 127: 574-80.
222. Epstein JI. PSA and PAP as immunohistochemical markers in prostate cancer. Urol Clin North Am 1993; 20: 757-70.
223. Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995; 1: 18-28.
224. Green R, Epstein JI. Use of intervening unstained slides for immunohistochemical stains for high molecular weight cytokeratin on prostate needle biopsies. Am J Surg Pathol 1999; 23: 567-70.
225. Parsons JK, Gage WR, Nelson WG, De Marzo AM. p63 protein expression is rare in prostate adenocarcinoma: Implications for cancer diagnosis and carcinogenesis. Urology 2001; 58: 619-24.
226. Luo J, Zha S, Gage WR, Dunn TA, et al. Alpha-methylacyl-CoA racemase: A new molecular marker for prostate cancer. Cancer Res 2002; 62: 2220-6.
227. Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol 2002; 26: 1161-8.
228. Rubin MA, Zhou M, Dhanasekaran SM, et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287: 1662-70.
229. Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. Alpha-Methylacyl-CoA racemase: A novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol 2002; 26: 926-31.
230. Zhou M, Shah R, Shen R, Rubin MA. Basal cell cocktail (34betaE12 p63) improves the detection of prostate basal cells. Am J Surg Pathol 2003; 27: 365-71.
231. Magi-Galluzzi C, Luo J, Isaacs WB, Hicks JL, de Marzo AM, Epstein JI. Alpha-methylacyl-CoA racemase: A variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am J Surg Pathol 2003; 27: 1128-33.
232. Sanderson SO, Sebo TJ, Murphy LM, Neumann R, Slezak J, Cheville JC. An analysis of the p63/alpha-methylacyl coenzyme A racemase immunohistochemical cocktail stain in prostate needle biopsy specimens and tissue microarrays. Am J Clin Pathol 2004; 121: 220-5.
233. Farinola MA, Epstein JI. Utility of immunohistochemistry for alphamethylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy. Hum Pathol 2004; 35: 1272-8.
234. Hameed O, Humphrey PA. Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol 2005; 22: 88-104.
235. Sheridan T, Herawi M, Epstein JI, Illei PB. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am J Surg Pathol 2007; 31: 1351-5.
236. Trpkov K, Bartczak-McKay J, Yilmaz A. Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens. Am J Clin Pathol 2009; 132: 211-20.
237. Oliai BR, Kahane H, Epstein JI. Can basal cells be seen in adenocarcinoma of the prostate?: An immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody. Am J Surg Pathol 2002; 26: 1151-60.
238. Ali TZ, Epstein JI. False positive labeling of prostate cancer with high molecular weight cytokeratin: P63 a more specific immunomarker for basal cells. Am J Surg Pathol 2008; 32: 1890-5.
239. Osunkoya AO, Hansel DE, Sun X, Netto GJ, Epstein JI. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: Report of 21 cases. Am J Surg Pathol 2008; 32: 461-7.
240. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8.
241. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol 2009; 6: 429-39.
242. Esgueva R, Perner S, Christopher JL, et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol 2010; 23: 539-46.
243. Scheble VJ, Braun M, Beroukhim R, et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 2010; 23: 1061-7.
244. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: Clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 2010; 13: 228-37.
245. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010; 12: 590-8.
246. Yaskiv O, Zhang X, Simmerman K, et al. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am J Surg Pathol 2011; 35: 1062-8.
247. He H, Magi-Galluzzi C, Li J, et al. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with 'atypical glands suspicious for cancer'. Am J Surg Pathol 2011; 35: 608-14.
248. Bostwick DG, Grignon DJ, Hammond ME, et al. Prognostic factors in prostate cancer. College of American Pathologists consensus statement. Arch Pathol Lab Med 2000; 124: 995-1000.
249. Netto GJ, Epstein JI. Theranostic and prognostic biomarkers: Genomic applications in urological malignancies. Pathology 2010; 42: 384-94.
250. Netto GJ. Molecular diagnostics in urologic malignancies: A work in progress. Arch Pathol Lab Med 2011; 135: 610-21.
251. Wikstrom P, Bergh A, Damber JE. Transforming growth factor-beta1 and prostate cancer. Scand J Urol Nephrol 2000; 34: 85-94.
252. Sanchez D, Rosell D, Honorato B, Lopez J, Arocena J, Sanz G. Androgen receptor mutations are associated with gleason score in localized prostate cancer. BJU Int 2006; 98: 1320-5.
253. Kremer CL, Klein RR, Mendelson J, et al. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006; 66: 1203-12.